✨ Free AI Report
Tempest Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Tempest Therapeutics, Inc.
Company Research

Tempest Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Tempest Therapeutics is a clinical-stage oncology company developing first-in-class small molecule therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. The company's lead program, A...

Analyst-debate audio for Tempest Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Tempest Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Clinical-stage biotech with differentiated small molecule approach, strong partnership validation, and pipeline expansion...

Read the full analyst-debate transcript →
Industry Oncology/Immuno-Oncology - Clinical Stage Biotechnology
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Tempest Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Tempest Therapeutics, Inc. Overview

Pro stress-test →

Tempest Therapeutics is a clinical-stage oncology company developing first-in-class small molecule therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. The company's lead program, Amezalpat (TPST-1120), is advancing in a pivotal Phase 1b/2 study in collaboration with Roche for hepatocellular carcinoma and has demonstrated clinical activity across multiple cancer types.

Strategic Profile

Pro stress-test →

Tempest differentiates through dual-mechanism small molecules designed to activate both tumor killing and immune responses, partnering with pharmaceutical leaders like Roche to de-risk development. The company recently acquired dual-targeting CAR-T programs from Factor Bioscience to expand its pipeline and extend runway while maintaining a capital-efficient strategy with partner-funded programs.

Competitive Landscape

Pro stress-test →

Tempest competes in the oncology space against both large pharma and clinical-stage biotech developers. Direct competitors include other immuno-oncology and small molecule cancer therapy companies, but Tempest's differentiation lies in its dual tumor-targeted and immune-mediated mechanism approach combined with validation from Roche partnership, positioning it as a focused player in the competitive immuno-oncology landscape.

Industry Context

Tempest Therapeutics, Inc. operates in Oncology/Immuno-Oncology - Clinical Stage Biotechnology.

Key facts

Founded: 2011 · Headquarters: Brisbane, CA, United States

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Tempest Therapeutics, Inc..

  • Lead program Amezalpat advancing in pivotal study with Roche, standard of care regimen in hepatocellular carcinoma with Phase 1b/2 data showing clinical activity
  • Recently acquired dual-targeting CAR-T programs (Feb 2026) designed to expand portfolio and extend cash runway with partner-funded development approach
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Announced strategic plan for recently acquired dual-targeting CAR-T assets from Factor Bioscience
  • February 2026Closed acquisition of dual-targeting CAR-T programs
  • +1 moreTrack every material event for Tempest Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Tempest Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Immuno-oncology small moleculesTraditional checkpoint inhibitors and targeted oncology therapies→CAR-T and cellular immunotherapyCell-based cancer therapies competing with Tempest's acquired CAR-T programs→

Compare Tempest Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Tempest Therapeutics, Inc. operates in Oncology/Immuno-Oncology - Clinical Stage Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology/Immuno-Oncology - Clinical Stage Biotechnology research →
NEW · MCP server

Ask your AI assistant about Tempest Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Tempest Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Tempest Therapeutics, Inc. do this quarter?”
“Is Tempest Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Tempest Therapeutics, Inc. do?+
Tempest Therapeutics is a clinical-stage oncology company developing first-in-class small molecule therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. The company's lead program, A...
What is Tempest Therapeutics, Inc.'s Cyborg Score?+
Tempest Therapeutics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Tempest Therapeutics, Inc.'s main competitors?+
Named competitors include Immuno-oncology small molecules, CAR-T and cellular immunotherapy. The full competitive landscape is in the AskCyborg report.
How can I get the full Tempest Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Tempest Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Tempest Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Oncolytics Biotech Inc.